A Phase 1/2 Study of EG-70 As an Intravesical Administration to Patients with BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment

Protocol No

ENGENE-EG-70-101-LEGEND

Staff Member

Scott Johnson

Phase

I/II

Summary

This project is being done to evaluate the safety and tolerability of EG-70, a gene therapy, which is given inside the bladder, and its effectiveness on eliminating bladder tumors in patients with Non Muscle Invasive Bladder Cancer (NMIBC).

Objective

EG-70 in NMIBC Patients Who Are BCG-Unresponsive and High-Risk NMIBC Patients Who Have Been Incompletely Treated With BCG or Are BCG-Naïve

Study Sites

Froedtert Hospital

Status

OPEN TO ACCRUAL